Active Smallcap & Microcap Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$IDVV: Winners Waygers Adspot -- In this commercial, we showcase how Winners Waygers can give you the winning edge with expert insights, in-depth analysis, and top-tier picks for all major sports. Whether you're a seasoned bettor or just getting started, our strategies will help you make informed decisions and come out on top.
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$YGMZ News: MingZhu Logistics to Acquire HOLDCO 36 in Transformational Business Combination
SHENZHEN, China, Sept. 12, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced the acquisition of HOLDCO 36 in a transformational business combination. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals.
Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu, commented, "As part of our active M&A process, we have evaluated a series of potential transactions, with regard to long-term potential, valuation, and alignment with building shareholder value. We are excited about the proposed acquisition of HOLDCO 36 because it would immediately transform our business into higher growth, burgeoning market segments with a favorable regulatory environment and underlying demand catalysts. Upon successful deal closure and integration, we would expect to see a meaningful creation of value for all shareholders."
For assets and projects being injected, parties are with explicit understanding that the projects contributed by HOLDCO 36 and their conditions may change but new projects are always being secured and developed to either be added or be replacing non-active ones. Initial business assets and operations being acquired are expected to include:
Green Fuel Smart Trading Platform: A comprehensive global distribution platform for biofuels, natural gas, hydrogen-based fuels, methanol, and related equipment. This platform aims to establish itself as the OPEC of green biofuels, facilitating the trade and distribution of sustainable fuel sources worldwide.
EPC+O: Engineering, Procurement, Construction, and Operations for biomass energy, and new energy systems such as wind, solar, storage, hydrogen, and ammonia EPC engineering productions systems. Using the existing ECaaS to provide distributed biomass "carbon-electricity-biomass energy" co-generation solutions. The business provides wind, solar, storage, green hydrogen, and green ammonia and green fuel EPC consulting services to clients in Americas, Asia, Africa and Europe.
Power Leasing and Energy: Developed an intelligent financial service platform for sales and lease financing for green and lightweight vessels, maritime equipment and lightweight materials for vessels.
Digital Energy Services Segment for the Steel Industry: Innovating a smart virtual power plant for closed-loop virtual scenarios targeting steel mills worldwide, supporting local distributed energy operations and usage. Managing national zero-carbon industrial parks for the steel industry and voluntary carbon reduction, which provides carbon credit, supply chain carbon verification, green certificate trading and verification.
About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)
Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit http://ir.szygmz.com.
Forward-Looking Statements
The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.
https://c212.net/c/img/favicon.png?sn=CN05051&sd=2024-09-12 View original content:https://www.prnewswire.com/news-releases/mingzhu-logistics-to-acquire-holdco-36-in-transformational-business-combination-302246593.html
SOURCE MingZhu Logistics Holdings Limited
$YGMZ News: MingZhu Logistics to Acquire HOLDCO 36 in Transformational Business Combination
SHENZHEN, China, Sept. 12, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced the acquisition of HOLDCO 36 in a transformational business combination. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals.
Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu, commented, "As part of our active M&A process, we have evaluated a series of potential transactions, with regard to long-term potential, valuation, and alignment with building shareholder value. We are excited about the proposed acquisition of HOLDCO 36 because it would immediately transform our business into higher growth, burgeoning market segments with a favorable regulatory environment and underlying demand catalysts. Upon successful deal closure and integration, we would expect to see a meaningful creation of value for all shareholders."
For assets and projects being injected, parties are with explicit understanding that the projects contributed by HOLDCO 36 and their conditions may change but new projects are always being secured and developed to either be added or be replacing non-active ones. Initial business assets and operations being acquired are expected to include:
Green Fuel Smart Trading Platform: A comprehensive global distribution platform for biofuels, natural gas, hydrogen-based fuels, methanol, and related equipment. This platform aims to establish itself as the OPEC of green biofuels, facilitating the trade and distribution of sustainable fuel sources worldwide.
EPC+O: Engineering, Procurement, Construction, and Operations for biomass energy, and new energy systems such as wind, solar, storage, hydrogen, and ammonia EPC engineering productions systems. Using the existing ECaaS to provide distributed biomass "carbon-electricity-biomass energy" co-generation solutions. The business provides wind, solar, storage, green hydrogen, and green ammonia and green fuel EPC consulting services to clients in Americas, Asia, Africa and Europe.
Power Leasing and Energy: Developed an intelligent financial service platform for sales and lease financing for green and lightweight vessels, maritime equipment and lightweight materials for vessels.
Digital Energy Services Segment for the Steel Industry: Innovating a smart virtual power plant for closed-loop virtual scenarios targeting steel mills worldwide, supporting local distributed energy operations and usage. Managing national zero-carbon industrial parks for the steel industry and voluntary carbon reduction, which provides carbon credit, supply chain carbon verification, green certificate trading and verification.
About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)
Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit http://ir.szygmz.com.
Forward-Looking Statements
The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.
https://c212.net/c/img/favicon.png?sn=CN05051&sd=2024-09-12 View original content:https://www.prnewswire.com/news-releases/mingzhu-logistics-to-acquire-holdco-36-in-transformational-business-combination-302246593.html
SOURCE MingZhu Logistics Holdings Limited
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$BIVI News: BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receivebulk of $13.1 million grant funding
Company anticipates Phase 2 trial to commence by early 2025
CARSON CITY, Nev., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the U.S. Army Medical Research and Development Command, Office of Human Research Oversight, (OHRO) has approved BioVie’s plan to evaluate bezisterim for the treatment of neurological symptoms that are associated with long COVID. FDA had previously reviewed and approved the study as Safe to Proceed in August 2024. Approval from OHRO is the last scientific review milestone needed for the Company to receive the additional $12.6 million in grant funding from the U.S. Department of Defense (DOD) and initiate Phase 2 testing in long COVID.
The planned Phase 2 study is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID.
Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. The Centers for Disease Control recently reported that more than 17 million adults in the United States currently or previously had long COVID.1 Symptoms include cognitive dysfunction and fatigue and are debilitating. No therapies have proven effective for treatment to date. Chronic inflammation is one of the main hypotheses that researchers have proposed to explain the persistence of symptoms in long COVID.3 Specifically in individuals with “brain fog,” sustained systemic inflammation and persistent localized blood-brain-barrier (BBB) dysfunction are key physiological features.5 Bezisterim permeates the BBB and has been shown to modulate inflammation via the activation of NF-kB, thus representing a novel oral treatment targeting a suspected underlying cause of long COVID symptoms.
Terms of the Department of Defense Award
The work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $499,200 for the planning phase with the option, if approved, to receive an additional $12.6 million, to initiate a clinical trial once the planning phase has concluded and milestones have been met, through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.
About Long COVID
Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. Common symptoms include lingering loss of smell and taste, hearing loss, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented. The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently or previously have long COVID.1 The loss in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be $3.7 trillion.2 To date there are no non-pharmacological or pharmacological therapies proven effective for treatment of long COVID.
Chronic inflammation is one of the main hypotheses that researchers have proposed to explain the persistence of symptoms in long COVID.3 The expression of proteins associated with inflammation (LGALS9, CCL21, CCL22, TNF, CXCL10 and CD48) and immune regulation (IL1RN and CD22) have been shown to be elevated in individuals with long COVID versus full-recovered individuals.4 Specifically in individuals with “brain fog,” sustained systemic inflammation and persistent localized blood-brain-barrier (BBB) dysfunction are key physiological features.5 Thus, drugs modulating inflammation, and that work to regulate the BBB integrity, could represent potential therapeutic mechanisms for treating neurological symptoms of long COVID.
About Bezisterim
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. Bezisterim has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFkB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). NE3107 has been shown to modulate the activation of NFkB and thus modulate inflammation.
Bezisterim is also being investigated for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from AD. A Phase 2 study of bezisterim in PD (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
References
1 Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135–136. DOI: http://dx.doi.org/10.15585/mmwr.mm7306a4.
2 Cutler, David M. 2022 The economic costs of Long COVID: An update. long_covid_update_7-22.pdf (harvard.edu)
3 Evans RA, Leavy OC, Richardson M, et al. Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine. 2022;10(8):761-775.
4 Yin K, Peluso MJ, Luo X, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nature Immunology. 2024;25:218-225.
5 Greene C, Connoly R, Brennan D, et al. Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nature Neuroscience. 2024;27:421-432.
For Investor Relations Inquiries:
Bruce Mackle
Managing Director, LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
For Media Relations Inquiries:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com
https://www.globenewswire.com/newsroom/ti?nf=OTIzMDIzNCM2NDc3MzQyIzUwMDA3OTY2Ng==
https://ml.globenewswire.com/media/ZDllNTU2ZGUtMzJhZi00NGRlLWE3NDYtZTNlN2Y4MGNhNWRiLTUwMDA3OTY2Ng==/tiny/BioVie-Inc-.png
Source: BioVie, Inc.
Yes Blazing Stocks, official news from the company is the only valid material for real investors as it is fully accountable to the SEC for accuracy and truthfulness. And, of course, it does not matter if it is one day old or longer. Everything else posted on chat boards by anonymous persons with questionable agendas has no credibility at all. IVDN management will get its temporary reporting issues resolved and then we should certainly be getting more updates on the record sales year the company is having in 2024, as already reported in the most recent news below.
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$YGMZ News: MingZhu Logistics to Acquire HOLDCO 36 in Transformational Business Combination
SHENZHEN, China, Sept. 12, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced the acquisition of HOLDCO 36 in a transformational business combination. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals.
Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu, commented, "As part of our active M&A process, we have evaluated a series of potential transactions, with regard to long-term potential, valuation, and alignment with building shareholder value. We are excited about the proposed acquisition of HOLDCO 36 because it would immediately transform our business into higher growth, burgeoning market segments with a favorable regulatory environment and underlying demand catalysts. Upon successful deal closure and integration, we would expect to see a meaningful creation of value for all shareholders."
For assets and projects being injected, parties are with explicit understanding that the projects contributed by HOLDCO 36 and their conditions may change but new projects are always being secured and developed to either be added or be replacing non-active ones. Initial business assets and operations being acquired are expected to include:
Green Fuel Smart Trading Platform: A comprehensive global distribution platform for biofuels, natural gas, hydrogen-based fuels, methanol, and related equipment. This platform aims to establish itself as the OPEC of green biofuels, facilitating the trade and distribution of sustainable fuel sources worldwide.
EPC+O: Engineering, Procurement, Construction, and Operations for biomass energy, and new energy systems such as wind, solar, storage, hydrogen, and ammonia EPC engineering productions systems. Using the existing ECaaS to provide distributed biomass "carbon-electricity-biomass energy" co-generation solutions. The business provides wind, solar, storage, green hydrogen, and green ammonia and green fuel EPC consulting services to clients in Americas, Asia, Africa and Europe.
Power Leasing and Energy: Developed an intelligent financial service platform for sales and lease financing for green and lightweight vessels, maritime equipment and lightweight materials for vessels.
Digital Energy Services Segment for the Steel Industry: Innovating a smart virtual power plant for closed-loop virtual scenarios targeting steel mills worldwide, supporting local distributed energy operations and usage. Managing national zero-carbon industrial parks for the steel industry and voluntary carbon reduction, which provides carbon credit, supply chain carbon verification, green certificate trading and verification.
About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)
Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit http://ir.szygmz.com.
Forward-Looking Statements
The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.
https://c212.net/c/img/favicon.png?sn=CN05051&sd=2024-09-12 View original content:https://www.prnewswire.com/news-releases/mingzhu-logistics-to-acquire-holdco-36-in-transformational-business-combination-302246593.html
SOURCE MingZhu Logistics Holdings Limited
$YGMZ News: MingZhu Logistics to Acquire HOLDCO 36 in Transformational Business Combination
SHENZHEN, China, Sept. 12, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced the acquisition of HOLDCO 36 in a transformational business combination. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals.
Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu, commented, "As part of our active M&A process, we have evaluated a series of potential transactions, with regard to long-term potential, valuation, and alignment with building shareholder value. We are excited about the proposed acquisition of HOLDCO 36 because it would immediately transform our business into higher growth, burgeoning market segments with a favorable regulatory environment and underlying demand catalysts. Upon successful deal closure and integration, we would expect to see a meaningful creation of value for all shareholders."
For assets and projects being injected, parties are with explicit understanding that the projects contributed by HOLDCO 36 and their conditions may change but new projects are always being secured and developed to either be added or be replacing non-active ones. Initial business assets and operations being acquired are expected to include:
Green Fuel Smart Trading Platform: A comprehensive global distribution platform for biofuels, natural gas, hydrogen-based fuels, methanol, and related equipment. This platform aims to establish itself as the OPEC of green biofuels, facilitating the trade and distribution of sustainable fuel sources worldwide.
EPC+O: Engineering, Procurement, Construction, and Operations for biomass energy, and new energy systems such as wind, solar, storage, hydrogen, and ammonia EPC engineering productions systems. Using the existing ECaaS to provide distributed biomass "carbon-electricity-biomass energy" co-generation solutions. The business provides wind, solar, storage, green hydrogen, and green ammonia and green fuel EPC consulting services to clients in Americas, Asia, Africa and Europe.
Power Leasing and Energy: Developed an intelligent financial service platform for sales and lease financing for green and lightweight vessels, maritime equipment and lightweight materials for vessels.
Digital Energy Services Segment for the Steel Industry: Innovating a smart virtual power plant for closed-loop virtual scenarios targeting steel mills worldwide, supporting local distributed energy operations and usage. Managing national zero-carbon industrial parks for the steel industry and voluntary carbon reduction, which provides carbon credit, supply chain carbon verification, green certificate trading and verification.
About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)
Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit http://ir.szygmz.com.
Forward-Looking Statements
The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.
https://c212.net/c/img/favicon.png?sn=CN05051&sd=2024-09-12 View original content:https://www.prnewswire.com/news-releases/mingzhu-logistics-to-acquire-holdco-36-in-transformational-business-combination-302246593.html
SOURCE MingZhu Logistics Holdings Limited
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$RENB News: PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.
Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”
Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”
The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.
Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”
Key contributions from PersonalAIze include:
Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.
Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:
Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.
About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMzQ4MyM2NDg2NTQ4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OTFiMGU1MTQtYmY4NS00NmRlLWJkNzEtZmU2ZTUyNDBiMWE2LTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB News: PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.
Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”
Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”
The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.
Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”
Key contributions from PersonalAIze include:
Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.
Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:
Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.
About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMzQ4MyM2NDg2NTQ4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OTFiMGU1MTQtYmY4NS00NmRlLWJkNzEtZmU2ZTUyNDBiMWE2LTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$IDVV News: International Endeavors Corp. Announces Corporate Update
Las Vegas, Nevada--(Newsfile Corp. - September 18, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced the following update regarding progress made in its products and services.
Winners Waygers AI
The Winners Waygers beta service has been a success. Recently it has surpassed 4000 subscribers for its AI beta mode, and has crossed 50 subscribers for its professional service. We still anticipate reaching up to 100 pro subscribers by year end.
We are planning a couple things in the short term.
1) A video demonstration of how professionals use the AI
2) Development of a section on the site that allows pros to publish their picks to paid subscribers, creating additional revenue for WITech.
AI and Futures Trading
We are proud to announce that we have revived the AI trading service. The project was slowed down by previous management due to volatility and the resources required. Recent events such as the new ETF listings have allowed us to revive the project. We are currently developing an automated trader that trades listed ETFs as well as futures including the Mini and Micro S&P. We anticipate the service being available in November of this year.
WITech Professional Services
The WITech division of IDVV has been servicing several clients, providing custom automation and bots in Financial, and Health & Wellness sectors. We have expanded to the medical sector and are currently working on an LOI for the development of AI tools we believe will help scientists in R&D stages of drug development.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/223748_db14adfaa4a0cb5b_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223748
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/223748/130
$IDVV News: IEC Announces Update on Winners Waygers AI Powered Sports Handicapping Assistant
Las Vegas, Nevada--(Newsfile Corp. - September 10, 2024) - International Endeavors Corp. (OTC PINK: IDVV) ("IEC"), a technology holdings company announced that its artificial intelligence (AI) powered sports handicapping assistant has received additional pro subscribers, and its free beta version has topped 4000 subscribers.
Previously the company announced the launch of http://winnersaygers.com, a one of a kind artificial intelligence (AI) powered sports handicapping program in beta mode. Today we are pleased to announce that the free beta service has already received 4000 subscribers.
Current subscribers are being given picks that the AI is generating for the current NFL season, and plans are to convert subscribers to several paid options towards the end of October as the AI learns more data during the current season and becomes more efficient in its strategy. Last season the AI had over a 60% win rate, with an increasingly better win rate as the season progresses and the AI is able to use more up to date information. The current focus is building subscribers while perfecting the AI's thought process.
We have received additional subscribers for the professional AI handicapping version. Used by professional handicappers that helped to develop the tools and datasets for the AI. The pro tools do not make picks for professionals, but instead help them to acquire data at a much faster pace and allow them to increase their action. We anticipate reaching up to 100 subscribers by year end. Due to that nature of the handicapping community, Pro subscribers are acquired by referrals. Each paying a negotiable signup fee of up to $10,000 per license along with a monthly subscription of $1000 to $2000.
Winners Waygers spokesperson Marrion Lewis stated "We are on track with offering the service to the mainstream. Converting the pro version to a more user friendly mainstream style has been an undertaking, but one that our team is doing well. We're confident that a product will be there that can revolutionize the industry."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/222813_21b8d136c42aeaa5_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222813
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/222813/130
$IDVV News: IEC Announces Update on Winners Waygers AI Powered Sports Handicapping Assistant
Las Vegas, Nevada--(Newsfile Corp. - September 10, 2024) - International Endeavors Corp. (OTC PINK: IDVV) ("IEC"), a technology holdings company announced that its artificial intelligence (AI) powered sports handicapping assistant has received additional pro subscribers, and its free beta version has topped 4000 subscribers.
Previously the company announced the launch of http://winnersaygers.com, a one of a kind artificial intelligence (AI) powered sports handicapping program in beta mode. Today we are pleased to announce that the free beta service has already received 4000 subscribers.
Current subscribers are being given picks that the AI is generating for the current NFL season, and plans are to convert subscribers to several paid options towards the end of October as the AI learns more data during the current season and becomes more efficient in its strategy. Last season the AI had over a 60% win rate, with an increasingly better win rate as the season progresses and the AI is able to use more up to date information. The current focus is building subscribers while perfecting the AI's thought process.
We have received additional subscribers for the professional AI handicapping version. Used by professional handicappers that helped to develop the tools and datasets for the AI. The pro tools do not make picks for professionals, but instead help them to acquire data at a much faster pace and allow them to increase their action. We anticipate reaching up to 100 subscribers by year end. Due to that nature of the handicapping community, Pro subscribers are acquired by referrals. Each paying a negotiable signup fee of up to $10,000 per license along with a monthly subscription of $1000 to $2000.
Winners Waygers spokesperson Marrion Lewis stated "We are on track with offering the service to the mainstream. Converting the pro version to a more user friendly mainstream style has been an undertaking, but one that our team is doing well. We're confident that a product will be there that can revolutionize the industry."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
https://winnerswaygers.com
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone: 833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/222813_21b8d136c42aeaa5_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222813
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/222813/130
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc